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Abstract 
Lung cancer is the most common cancer type worldwide and the leading cause of cancer related deaths in the 
United States. The majority of newly diagnosed patients present with late stage metastatic lung cancer that is inoper-
able and resistant to therapies. High-throughput genomic technologies have made the identification of genetic 
mutations that promote lung cancer progression possible. Identification of the mutations that drive lung cancer 
provided new targets for non-small cell lung cancer (NSCLC) treatment and led to the development of targeted 
therapies such as tyrosine kinase inhibitors that can be used to combat the molecular changes that promote cancer 
progression. Development of targeted therapies is not the only clinical benefit of gene analysis studies. Biomarkers 
identified from gene analysis can be used for early lung cancer detection, determine patient’s prognosis and response 
to therapy, and monitor disease progression. Biomarkers can be used to identify the NSCLC patient population that 
would most benefit from treatment (targeted therapies or chemotherapies), providing clinicians tools that can be 
used to develop a personalized treatment plan. This review explores the clinical potential of NSCLC genetic studies on 
diagnosing and treating NSCLC.
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Introduction
Lung cancer is the leading cause of cancer related deaths 
in both men (28  %) and women (27  %) in the United 
States [1]. In 2015, the American Cancer Society esti-
mates 221,200 patients will be diagnosed with lung can-
cer and 158,040 deaths will occur due to this disease [1]. 
The majority of lung cancers are diagnosed at a late stage 
resulting in a 5 year survival rate (17 %) that is lower than 
breast (89  %), prostate (99  %), and colon carcinomas 
(65 %) [1]. The high death rates associated with lung can-
cer highlight the need for improved diagnosis and treat-
ment procedures. Lung cancer is broken down into two 
main categories, non-small-cell lung cancer (NSCLC) 
and small-cell lung cancer (SCLC) based on cell mor-
phology. NSCLC accounts for 85  % of all lung cancers 
and is subcategorized into pulmonary adenocarcinomas, 
squamous cell carcinomas, and large cell carcinomas 
(LCC) [2]. Forty, twenty-five, and ten percent of all lung 
cancers are diagnosed as adenocarcinomas, squamous 
cell carcinomas, and large cell carcinomas, respectively 
[2].
The first step to developing new treatments for any 
disease is to understand the molecular biology driv-
ing its progression. Development and implementa-
tion of high-throughput genomic technologies such as 
next generation sequencing (NGS) enable genotyping 
of tumors at a lower cost and quicker turn around than 
was previously possible [3, 4]. NGS and other nucleic 
acid sequencing technologies (reviewed in [3, 4]) have 
identified genetic mutations that drive lung cancer pro-
gression often referred to as “oncogenic drivers”. Discov-
ery of lung cancer drivers has led to the development of 
therapies that target cancer cells and inhibit the pathways 
that promote lung cancer growth and progression. The 
use of targeted therapies have led to an increase in sur-
vival of lung cancer patients with certain genetic altera-
tions such as epidermal growth factor receptor (EGFR) 
activating mutations and anaplastic lymphoma kinase 
(ALK) rearrangements [5–7]. Gefitinib, a small molecule 
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inhibitor for the EGFR receptor was approved for use to 
treat NSCLC in May of 2003 [6]. Gefitinib was one of 
the first tyrosine kinase inhibitors and targeted thera-
pies approved for NSCLC with aberrant activation of the 
EGFR pathway [8]. Gefitinib is an example of how dis-
coveries made by basic science researchers on molecular 
changes in cancers can translate to provide therapies that 
can be utilized in the clinic.
However, the clinical significance of studying lung can-
cer mutations goes beyond drug development. Investi-
gation and characterization of NSCLC mutations can 
also be used to identify biomarkers that can be used for 
early diagnosis and predicting patients’ prognosis and 
response to treatment that can be used to determine 
a personalized therapeutic regimen. This review will 
explore the clinical benefits of genetic mutation inves-
tigations for patients with NSCLC with an emphasis on 
use of gene biomarkers for diagnosis and treatment.
Review
Lung cancer mutations and targeted therapy
Mutations in NSCLC
NSCLC is a heterogeneous disease marked with a 
high rate of somatic mutations. Genetic analyses of the 
NSCLC subtypes lung adenocarcinomas and squamous 
cell carcinomas found a higher rate of mutations in these 
cancers than acute myelogenous leukemia, glioblastoma 
multiforme, and cancers of the breast, ovaries, and colon 
[9, 10]. The Cancer Genome Atlas (TCGA) research net-
work and other groups, have identified several genes 
altered (by mutations, amplification, or rearrangements) 
in adenocarcinomas such as: EGFR, EML4-ALK (Echino-
derm microtubule associated protein-like protein 4 fused 
with Anaplastic Lymphoma Kinase), KRAS (Kirsten rat 
sarcoma viral oncogene homolog), MET (mesenchy-
mal-epithelial transition factor), ROS1 (c-ros oncogene 
1), RET (rearranged during transfection), BRAF (v-Raf 
murine sarcoma viral oncogene homolog B1), and TP53 
(tumor suppressor protein 53) and in squamous cell 
carcinomas: FGFR1 (fibroblast growth factor receptor 
1), PIK3CA (phosphoinositide-3-kinase catalytic subu-
nit alpha isoform), DDR2 (discoidin domain receptor 
2), MET, SOX2 (SRY related HMG box gene 2), PTEN 
(phosphatase and tensin homolog), CDKN2A (TP53 and 
cyclin-dependent kinase inhibitor 2A) highlighted in 
Table 1 [9, 10].
A large majority of altered genes code for proteins that 
are involved in receptor tyrosine kinase (RTK) signaling, 
leading to the promotion of NSCLC cell proliferation, 
survival, migration, and invasion (Table  1) [9–13]. Sev-
eral mutations or amplifications occur in genes for the 
RTKs: EGFR, ALK, MET, ROS1, RET, FGFR1 and DDR2 
or in genes that help facilitate RTK downstream signaling 
events such as: KRAS, BRAF, and PIK3CA (phosphoi-
nositide-3-kinase (PI3K) family member) in NSCLC [9–
13]. PTEN mutations and/or deletions occur in 15–20  % 
of squamous cell carcinomas and leads to aberrant acti-
vation of the PI3K pathway (Table  1). Although genetic 
alterations occur in both adenocarcinomas and squamous 
cell carcinomas effecting RTK signaling, these NSCLC 
sub-types have different dominant mutations, amplifica-
tions, or rearrangements (Table 1). For example, EGFR and 
KRAS are two of the most commonly mutated genes in 
lung adenocarcinomas; however they are rarely mutated in 
lung squamous cell carcinomas (Table 1) [9, 10].
The advent of technology and assays that allow the 
sequencing and analysis of the genome has resulted 
in an influx of information regarding NSCLC and 
increased the number of possible therapeutic targets. 
The NSCL genetic alterations represented in Table  1 
barely scratches the surface in regards to the many dif-
ferent genomic abnormalities that have been identified. 
The question remains which of the identified muta-
tions constitute good targets for therapeutic interven-
tion in NSCLC? However, these genetic alterations are 
of interest to researchers for several reasons including; 
the rate of occurrence in NSCLC and/or the ability of 
these changes in the genome to drive oncogenesis. The 
rate of occurrence in NSCLC and the ability of these 
changes in the genome to drive oncogenesis are two 
criteria used to determine pharmaceutical targets [14]. 
In the next section, we will highlight the targeted thera-
pies that are currently approved or in development for 
NSCLC.
Targeted therapies for NSCLC
Identification of gene mutations, amplifications, and 
rearrangements in NSCLC provides a pool of new tar-
gets to be used in drug development. Targeted therapies 
include small molecular inhibitors and monoclonal anti-
bodies that bind and inhibit the molecular pathways that 
promote NSCLC progression. Introduction of targeted 
therapies to the clinic resulted in decreased toxicity and 
increased rate of disease-free survival for patients with 
NSCLC compared to those treated with standard chemo-
therapy [15–18]. Unfortunately, only a small percentage 
of patients with NSCLC are eligible for approved targeted 
therapies. Patients eligible for FDA approved targeted 
therapies (erlotinib, afatinib, crizotinib, and ceritinib) 
are those diagnosed with advanced stage lung adenocar-
cinomas with activating mutations in the EGFR gene or 
EML4-ALK fusions [2, 13, 19–22]. Lung squamous cell 
carcinomas and adenocarcinomas have differing genetic 
profiles and molecular drivers and therefore do not 
respond to the tyrosine kinase inhibitors approved for 
treatment of NSCLC [23].
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Several reviews have been published this year on 
NSCLC targeted therapies; therefore this review con-
tains a short description of targeted therapies approved 
or in development for NSCLC. For more information 
regarding targeted therapies in development and ongo-
ing clinical trials see the following reviews [2, 11, 13, 24]. 
Table  1 lists targeted therapies that are approved (bold 
font) or undergoing clinical trials for NSCLC and the 
effected pathways. Crizotinib is a tyrosine kinase inhibi-
tor that inhibits ALK and other RTKs such as MET and 
ROS1 [25]. Crizotinib is currently approved for treat-
ment of NSCLC that contain ALK rearrangements and 
is undergoing clinical trials for NSCLC with ROS1 rear-
rangements [26, 27]. Several compounds are undergoing 
clinical trials for targeted treatment of lung adenocarci-
nomas and lung squamous cell carcinomas with genetic 
alterations in MET, BRAF, ROS1, RET, FGFR1, and 
PIK3CA (Table  1). Examples of ongoing clinical trials 
can be seen in Table  2. Not all of the identified genetic 
abnormalities in NSCLC (KRAS, SOX2, CDKN2A, and 
TP53) are currently targetable by small molecule inhibi-
tors or monoclonal antibodies [11, 13, 28]. However, 
therapies that target downstream signaling pathways for 
KRAS such as MEK (mitogen-activated protein kinase 
kinase 1) inhibitors are being investigated [24].
One of the largest problems associated targeted thera-
pies is primary or acquired resistance. Primary resist-
ance to EGFR inhibitors have been found in patients that 
harbor KRAS or certain EGFR point mutations (T790) 
[29–31]. However, mutations of KRAS and EGFR are 
mutually exclusive [10]. Expression of Bim after treat-
ment with tyrosine kinase inhibitors is also associated 
with primary resistance. Patients who have low expres-
sion of the pro-apoptotic protein Bim or have polymor-
phisms altering the function of Bim have lower response 
to EGFR and ALK inhibitors [31]. Use of tyrosine kinase 
inhibitors gefitinib, erlotinib, and crizotinib for NSCLC 
treatment invariably leads to acquired drug resistance 
Table 1 Lung adenocarcinoma and  squamous cell carcinoma mutations, incidence, downstream effects, and  targeted 
therapies
N/A not available, currently not able to target efficiently with drugs, Mut mutations, Del deletions, Amp amplifications, Fus fusions





Downstream effect Targeted therapya Sources
Adenocarcinomas
 EGFR (mut) ~15 ↑ Proliferation, survival, angiogenesis,  
and metastasis
Gefitinib, erlotinib, afatinib, AZD9291, 
AZD8931
[10, 11]
 EML4-ALK (fus) 2–7 ↑Proliferation, survival, and migration Crizotinib, ceritinib, alectinib [11, 79, 80]
 KRAS (mut) ~30 ↑ Chemoresistance, proliferation, and 
survival
N/A [10]
 MET (amp) 3–5 ↑ Cell survival, proliferation, and metastasis Tivantinib, crizotinib cabozantinib, ornatu-
zumab
[11, 13, 24, 81]
 ROS1 (fus) 1–2 ↑ Survival Foretinib & crizotinib [13, 24]
 RET (fus) 1–2 ↑Proliferation Carbozantinib, vandetanib, ponatinib [11]
 BRAF (mut) 5–10 ↑ Resistance to EGFR inhibitors, proliferation, 
and survival
Debrafenib, sorafenib [10, 24]
 TP53 (mut) 46 ↑ Growth, ↓ apoptosis N/A [10, 11]
Squamous cell carcinomas
 FGFR1 (amp) 16–25 ↑ Proliferation, survival, and chemoresist-
ance; ↓ patient prognosis
Nintendanib, ponatinib, AZD4547, dovitinib [9, 11, 12, 82]
 PIK3CA (mut) 8–18 ↑ Proliferation and survival Buparlisib, PX-866, BYL719, GDC-0941 or 
inhibitors for AKT: AZD5363, MK-2206
[9, 11, 13, 24, 82]
 DDR2 (mut) 4 ↑ Cell migration, invasion, proliferation, and 
survival
Dasatinib [9, 13]
 MET (amp) 3 ↑ Cell survival, proliferation, and metastasis Tivantinib, crizotinib cabozantinib, onartu-
zumab
[12, 24, 81]
 SOX2 21 ↑ Proliferation N/A [9]
 PTEN (mut & del) 15–29 ↑PI3K signaling, proliferation, and survival PI3K inhibitors: buparlisib, PX-866, BYL719, 
GDC-0941 or inhibitors for AKT: AZD5363, 
MK-2206
[9, 11, 24, 82]
 TP53 (mut) 81 ↑ Growth, ↓ apoptosis N/A [9, 11, 12]
 CDKN2A (del) 51 ↑ Growth N/A [9]
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[32, 33]. Mutations in the EGFR gene (T790M) or altera-
tions in MET(amplification), BRAF(mutation), HER2 
(amplification), PIK3CA (mutation), or PTEN (loss) 
leads to gefitinib and erlotinib resistance [33]. Resist-
ance to ALK inhibitors occurs due to mutations in ALK 
(L1196M), amplifications of ALK, or activation of EGFR 
or KRAS that bypass the inhibition induced by tyrosine 
kinase inhibitor crizotinib [19, 34, 35]. Second generation 
inhibitors afatinib and ceritinib are approved for use in 
the FDA and have shown some promise in patients who 
were previously treated with first generation tyrosine 
kinase inhibitors for EGFR or ALK (respectively) [19, 34, 
36]. In a phase IIb/III trial, afatinib increased progres-
sion free survival (3.3 months) of patients with advanced 
NSCLC that progressed after treatment with erlotinib, 
gefitinib, or both compared to placebo group (1.1 months 
P < 0.0001) [36]. In a phase I trial, ceritinib in 114 patients 
with advanced NSCLC had an overall response rate of 
58 % [19, 34]. Response rate for ceritinib in patients who 
had disease progression after use of crizotinib was 56 %. 
Genetic analysis of 19 tumors from patients that previ-
ously had crizotinib therapy, showed patients responded 
to ceritinib even if they had the presence of ALK resist-
ance mutation (L1196M) [19, 34].
Targeted therapeutics is a growing field in which 
there is a great need for therapies (1) that can be used 
for squamous cell carcinoma patients and (2) that over-
come resistance associated with the available targeted 
therapies. Targeted therapies give the clinician the abil-
ity to select NSCLC treatments based on the molecular 
characteristics of the patients’ cancer. Personalized ther-
apy addresses the fact that cancers are a heterogeneous 
disease in which no two tumors are identical. The gen-
eralized therapeutic approach commonly used does not 
take into account molecular mechanisms that lead to 
chemoresistance and recurrence [37]. Clinical validation 
is needed to determine if genetic analysis based selec-
tion of targeted therapies can increase patient survival. 
Several clinical studies are evaluating the use of genetic 
analysis to determine a personalized treatment plan for 
NSCLC patients using several different arms of targeted 
treatments. Two examples of ongoing clinical trials can 
be found in Table 2 in which researchers are using thera-
pies that target pathways modulated in NSCLC. Choos-
ing the optimal treatment is a difficult process, but the 
implementation of biomarkers can provide clinicians 
with information that can be used in selection of NSCLC 
treatment.
Biomarkers and NSCLC
Seventy-nine percent of patients diagnosed with lung 
cancer present with regional or distant metastases [1]. 
The 5 years survival rate for patients diagnosed with early 
stage lung cancer is 27 and 50  % greater than patients 
diagnosed with regional or distant metastases, respec-
tively [1]. The National Lung Screening Trial found that 
early detection of lung cancer using low-dose computed 
tomography (CT) resulted in a 20  % reduction in mor-
tality [38]. However, CT scans are unable to differentiate 
between benign and malignant lesions. Follow-up lung 
biopsies found that 96.4  % of the lesions found by CT 
were benign [38]. The high percentage of false positive 
results, costs of CT scans, and stress to patients suggests 
CT scans are not practical for early lung cancer screen-
ing. Although early diagnosis gives an advantage toward 
patient survival, 36 % of patients with stage I to II NSCLC 
recur 5 years after surgery [39]. Gene mutations and pro-
tein expression can impact patient survival. For exam-
ple, patients with deletions in exon 19 and mutations in 
exon 21 had a longer overall survival after treatment with 
gefitinib or erlotinib [7, 40]. High expression of ERCC1 
(excision repair cross-complementation group 1) mRNA 
or protein is associated with decreased overall survival in 
NSCLC patients treated with platinum based therapies 
[41, 42].
Investigation of genetic alterations has enabled the 
identification of key molecular changes that occur dur-
ing the pathogenesis of lung cancer that can be used as 
biomarkers for detecting and treating lung cancer. Bio-
markers are detectable changes in DNA, RNA, protein, 
lipids, etc., that can be used for (1) detecting and diag-
nosing lung cancer, (2) determining prognosis, (3) pre-
dicting patient response to therapy, and 4) choosing an 
optimal treatment regimen for NSCLC patients [43–45]. 
Utilization of biomarkers will allow clinical oncologists 
to select a personalized treatment option that will give 
the patient the greatest chance of survival, decrease tox-
icity, and unnecessary procedures [44, 45]. Investigative 
studies for lung cancer biomarkers have been conducted 
using cancer tissue, blood, lung condensate, sputum, and 
saliva samples [46–51]. In the following sections, we will 
explore the clinical potential and benefits of using gene 
biomarkers in the clinic to detect and treat NSCLC.
Gene biomarkers: implications for early detection 
and diagnosis of NSCLC
Biomarkers extracted from biofluids (blood, sputum, and 
saliva) are under investigation for the diagnosis of lung 
cancer without the use of invasive procedures required 
to collect lung cancer or bronchial epithelial cells [52, 
53]. Blood samples extracted from NSCLC patients 
contain circulating cell free DNA (cfDNA; normal and 
tumor DNA), RNA, and mononuclear and tumor cells 
all of which are sources of genetic material that can be 
used for identification of biomarkers to detect lung can-
cer [52, 54, 55]. A multi-marker panel consisting of the 
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circulating expression of cfDNA, mRNA expression of 
peptidylarginine deaminase type 4 (PADA) and proplate-
let basic protein (PPBP) was able to discriminate between 
patients with NSCLC and controls with a sensitivity 
of 92 % and a specificity of 89 % [56]. Increased expres-
sion of cfDNA can be detected in the peripheral blood 
of NSCLC patients as early as stage IA compared to con-
trols demonstrating the potential of cfDNA to be used 
in early detection of lung cancer [57]. Although cfDNA 
can be detected as early as stage I, it is associated with 
a lower sensitivity. Using a new strategy to analyze cir-
culating tumor cells known as cancer personalized profil-
ing by deep sequencing (CAPP-Seq), Newman et al. were 
able to detect circulating tumor DNA in 100 % of NSCLC 
between the stages of II–IV and 50 % of stage I tumors 
with specificity of 96 % for both groups [58]. Studies in 
peripheral blood mononuclear cells have examined gene 
expression profiles in order to identify biomarkers that 
can be used for diagnosis of breast, urinary bladder, and 
lung cancers [54, 59, 60]. Showe et al. [54] identified a 29 
mRNA signature from peripheral mononuclear cells of 
patients with NSCLC that distinguished with 91 % sensi-
tivity and 80 % specificity patients with cancer from con-
trols. Clinical trials are vital to validate biomarkers before 
use in the clinic. Search of http://www.clinicaltrials.gov 
yielded only one clinical trial based on our search param-
eters that is looking for gene biomarkers in the blood that 
can be used for diagnosis of NSCLC (http://www.clinical-
trials.gov identifier NCT02169349; Table 3).
Gene expression analyses of saliva and sputum sam-
ples have identified possible biomarkers that have clini-
cal potential in detecting NSCLC. In 2012 Zhang et  al. 
[46] identified and pre-validated seven mRNA transcripts 
[BRAF (v-raf murine sarcoma viral oncogene homolog 
B1), CCNI (cyclin I) EGFR, FGF19 (fibroblast growth 
factor 19), FRS2 (fibroblast growth factor receptor sub-
strate 2), GREB1 (growth regulation by estrogen in breast 
cancer 1), and LZTS1 (leucine zipper, putative tumor 
suppressor 1)] expressed in the saliva from patients with 
NSCLC. A multi-marker panel measuring mRNA expres-
sion of CCN1, EGFR, FGF19, FRS2, and GREB1 in saliva, 
differentiated patients with lung cancer from controls 
with a sensitivity of 93.75 % and specificity of 82.8 % [46]. 
Currently, a clinical validation study evaluating the detec-
tion of lung cancer using a single or multi-marker panel 
of the seven mRNA transcripts identified by Zhang et al. 
[46] is recruiting patients with lung lesions suspected of 
having lung cancer (NCT02294578; Table 3).
Gene alterations have been identified from sputum 
samples collected from NSCLC patients suggesting spu-
tum can be used to identify genetic abnormalities in lung 
cancer [51, 61, 62]. Gene analysis performed on the spu-
tum of 49 NSCLC patients, 49 patients with COPD, and 
49 healthy smokers, identified 15 genes with significant 
differences in copy number in patients with NSCLC com-
pared to controls. A multi-marker panel containing 6 of 
the identified altered genes (ENO1, FHIT, HYAL2, SKP2, 
CDKN2A, and 14-3-3zeta) were able to differentiate 
between patients with NSCLC and control with 86.7  % 
specificity and 93.9  % sensitivity [63]. Further studies 
are needed to validate biomarkers in the sputum prior 
to use in the clinic. The ability to detect the presence of 
NSCLC from fluid samples can aid in decreasing the cost 
and stress to patients associated with current methods 
(biopsies and CT scans) used to differentiate between a 
benign and malignant small nodule that detected using 
CT scans. However, more sensitive methods are needed 
to detect the presence of stage I lung cancer.
Gene biomarkers: implications for use as NSCLC predictive 
and prognostic biomarkers
Several studies have examined the genetic profiles of 
NSCLC to identify prognostic and predictive gene bio-
markers. A prognostic biomarker is a measureable fac-
tor that can be used to ascertain the likelihood of an 
event such as; recurrence, drug resistance, or metastasis 
to occur irrespective of treatment [64]. Whereas pre-
dictive biomarkers provide information concerning the 
benefits of a treatment for the patient such as increased 
survival or tumor response [64]. Prognostic and predic-
tive biomarkers can be used to tailor chemotherapy treat-
ments based on gene mutations or expression resulting 
in increased patient survival. Several studies have inves-
tigated the efficacy of selecting chemotherapies based on 
expression of genes ERCC1 (excision repair cross com-
plementing gene 1), RRM1 (ribonucleotide reductase), 
TS (thymidylate synthase), TUBB3 (type III β-tubulin), 
and BRCA1 (breast cancer susceptibility gene 1) that 
are associated with chemoresistance in NSCLC [42, 47, 
48, 65]. Miao et al. [48] conducted a retrospective anal-
ysis and found that chemotherapy selection based on 
gene expression of ERCC1 (platinum based therapies 
resistance), RRM1 (gemcitabine resistance), TS (pem-
etrexed resistance), and TUBB3 (vincristine resistance) 
in tumors resulted in higher rate of disease free survival 
[1  year  =  66.7 vs. 44.7  % (P  =  0.014); 2  year 48.9 vs. 
27.2  % (P =  0.010)] in stage IIIA NSCLC patients [48]. 
Furthermore, Zhang et al. [65] found that patients given 
a tailored chemotherapy regimen based on presence of 
ERCC1, RRM1, and TUBB3 had higher 1  year survival 
rates (69.5  %) and longer progression free survival time 
(5.2 months) compared to patients given standard treat-
ment of gemcitabine plus cisplatin [survival rate = 40.9 % 
(P = 0.021) and progression free survival time 4.1 months 
(P = 0.0260)]. The results from these studies suggest per-
sonalized therapy selection based on expression of genes 
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associated with chemoresistance can be used to increase 
patient response. However, these studies did not find 
a statistically significant change in overall survival and 
more validation needs to be done before implementation 
in the clinic. Clinical validation studies NCT01424709, 
NCT00792701, and NCT02145078 are investigating the 
effect of selecting chemotherapy for NSCLC patients 
using expression of ERCC1, TS, RRM1, and BRCA1, 
mRNA in different combinations, on patient response 
and survival (Table 4).
The implementation of targeted therapies has resulted 
in a need for predictive biomarkers to determine patient 
population that would benefit from their use. EGFR 
mutations and ALK rearrangements are examples of pre-
dictive biomarkers that are tested prior to use of gefitinib, 
erlotinib, afatinib, crizotinib, and ceritinib [7, 66, 67]. In 
2013, the College of American Pathologists, International 
Association for the Study of Lung Cancer, and Associa-
tion for molecular Pathology established guidelines for 
the molecular testing of all advanced stage lung adeno-
carcinomas for EGFR mutations and ALK rearrange-
ments prior to treatment [68]. Several clinical trials are 
being conducted to test the efficacy of new targeted ther-
apies in conjunction with evaluating predictive biomark-
ers for the treatment of NSCLC. An example of this can 
be found in Table  2 in which the gene copy number of 
FGFR1 is being tested to predict patient response to the 
tyrosine kinase inhibitor nintedanib undergoing clinical 
evaluation for treatment of NSCLC with FGFR1 amplifi-
cations (Table 2).
Molecular profiling of NSCLC is generally per-
formed on biopsies that contain a small amount of 
tumor and stromal cells and are extracted by using 
invasive bronchoscopy or transthoracic needle biopsy. 
Therefore biomarker analysis using tumor tissue for 
selection of treatment for patients must be highly 
sensitive, selective, cost effective, reproducible, and 
have a quick turn-around time [4, 44, 69]. Further-
more, different areas of a tumor and metastatic sites 
can have dissimilar genetic profiles making it dif-
ficult to identify and extract biomarkers to monitor 
disease progression and response to therapy [4, 44, 
69]. Peripheral blood samples containing circulating 
tumor cells (CTC) and free circulating tumor DNA 
(ctDNA) may provide a source to measure biomark-
ers prior to treatment. EGFR activating mutations 
associated with response to TKIs have been identi-
fied in DNA extracted from CTCs and in free ctDNA 
[70–73]. EGFR mutations analyzed from peripheral 
blood samples correlated with DNA analysis from 
matched tumor tissue; however ctDNA had a greater 
sensitivity for detecting EGFR mutations than DNA 
extracted from CTCs [70, 72, 73]. An analysis con-
ducted by Yung et al. [73] was able to identify patients 
with EGFR mutations using ctDNA from plasma with 
an 92 % sensitivity and 100 % specificity compared to 
analysis using DNA extracted from NSCLC patients. 
Mutations in KRAS and ALK rearrangements have 
also been found in analyses on CTCs or ctDNA and 
correlate with mutation analysis in match tumor sam-
ples [74, 75]. A list representing ongoing clinical trials 
investigating the use of biomarkers as predictive and 
prognostic factors from tumors and peripheral blood, 
can be found in Table 4.
Biomarkers extracted from blood, saliva, and sputum 
have the possible advantage of providing early diagnosis 
of lung cancer and information that can be used for treat-
ment selection without the use of invasive procedures. 
Multiple specimens can also be analyzed allowing the 
capabilities to monitor disease progression and response 
to therapy. This review highlighted several biomarker 
studies for use detecting and treating NSCLC. However, 
validation studies and standardization of biomarker anal-
ysis are needed before biomarkers are employed in the 
clinic [76].
Conclusions
Analysis of gene alterations has provided invaluable 
insight that has spurred the development of targeted 
therapies for NSCLC. The benefits of understanding the 
molecular changes promoting lung carcinogenesis go 
beyond drug development. Identification and validation 
of biomarkers that can be used to provide early detec-
tion and aid in the selection of personalized therapy 
are currently undergoing clinical testing. Biomarkers 
for early detection of lung cancer have the potential to 
be combined with current CT scans or alone to iden-
tify the presence of cancers without requiring invasive 
procedures. Utilization of biomarkers in the clinic for 
determination of patients’ prognosis and response to 
therapy are invaluable tools that may increase patient 
survival and decrease toxicity due to ineffective treat-
ments. However, understanding the genetic changes in 
NSCLC is just one side of the coin. Transcriptomic and 
proteomic studies not covered in this review are vital 
in understanding the downstream effect of gene muta-
tions; and in identifying other mechanisms that pro-
mote cancer progression. DNA methylation, miRNA, 
and protein expression are all possible types of biomark-
ers that can be used for early detection, determining 
prognosis, and predicting patient response to therapy in 
NSCLC [43, 77, 78].
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